Home › Companies › REGENERON PHARMACEUTICALS INC. › 2024-2025

REGENERON PHARMACEUTICALS INC. 2024-2025 Proxy Voting Records

Compiled from SEC Form N-PX filings and REGENERON PHARMACEUTICALS INC.’s Form 8-K, filed 2025-06-18 (Item 5.07 on EDGAR). Page generated 02 October 2026.

22Reported items
1,011Asset managers
10,208Fund votes
2025-06-13Meeting date

Proxy season: 2023-2024 2024-2025 2025-2026

Explore REGENERON PHARMACEUTICALS INC. in the interactive database Compare manager voting policies

Official 2024-2025 meeting results reported by REGENERON PHARMACEUTICALS INC.

These tallies are REGENERON PHARMACEUTICALS INC.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed 2025-06-18 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

REGENERON PHARMACEUTICALS INC. — official shareholder meeting results, meeting held 2025-06-13
Ballot item	For	Against	Abstain	Withheld	Broker non-votes	Outcome
Elect Director: Bonnie L. Bassler, Ph.D.	87,348,630	18,594,454	51,195	--	5,601,648	Majority: yes
Elect Director: Michael S. Brown, M.D.	77,025,558	28,913,874	54,847	--	5,601,648	Majority: yes
Elect Director: Leonard S. Schleifer, M.D., Ph.D.	99,271,439	6,672,701	50,139	--	5,601,648	Majority: yes
Elect Director: George D. Yancopoulos, M.D., Ph.D.	101,367,161	4,089,290	537,828	--	5,601,648	Majority: yes
Proposal 2: Ratification of Appointment of Independent Registered Public Accounting Firm The proposal to ratify the appointment of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31,	105,462,255	6,078,716	54,956	--	--	Majority: yes
Proposal 3: Advisory Vote on Executive Compensation The resolution to approve, on an advisory basis, the compensation of the Company's named executive officers as disclosed in the Company's definitive proxy statement on Schedule 14A filed April 29, 2025 was ap	98,781,758	7,100,590	111,931	--	5,601,648	Majority: yes
Proposal 4: Amendment to the Company's Certificate of Incorporation to Declassify the Board of Directors The proposal to amend the Company's Certificate of Incorporation to declassify the board of directors was approved based upon the following votes:	85,711,231	20,226,748	56,300	--	5,601,648	Majority: yes
Proposal 5: Two Amendments to the Company's Certificate of Incorporation to Eliminate Supermajority Vote Requirements Proposal 5(a) – Amendment to Article IV, Section 2(e)(8) of the Company's Certificate of Incorporation Relating to the Mandatory Conversion of	85,490,681	2,279,384	142,814	--	5,601,648	Majority: yes
Proposal 9	85,490,182	20,360,243	143,854	--	5,601,648	Majority: yes

Source: REGENERON PHARMACEUTICALS INC., Form 8-K, filed with the SEC on 2025-06-18 — read the filing on EDGAR.

How asset managers voted at the REGENERON PHARMACEUTICALS INC. 2024-2025 meeting

Each item below shows how the 1,011 asset managers that disclosed a REGENERON PHARMACEUTICALS INC. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report. These are reported items, not a count of the ballot: fund filings describe one ballot item in different words. Two descriptions are shown as one item only on evidence — the same text (or one cut short of the other), the same director nominee, or a match to the same row of REGENERON PHARMACEUTICALS INC.’s own Form 8-K tally — never because they merely read alike. A description that could not be joined that way is listed on its own, so one ballot item can appear more than once.

1. Proposal to approve on an advisory basis executive compensation.

SECTION 14A SAY-ON-PAY VOTES

Meeting held 2025-06-13.

Combines 5 wordings of this item as funds reported it.

95% fund support · no official result

FOR 95%

The 966 asset managers below cast 95% of the shares they voted on this item FOR (90,632,175 for, 5,246,471 against).

FOR: 90,632,175 (94.5%)AGAINST: 5,246,471 (5.5%)ABSTAIN: 17,973 (0.0%)NOT VOTED: 8,018 (0.0%)

Largest asset managers voting on “Proposal to approve on an advisory basis executive compensation.” at REGENERON PHARMACEUTICALS INC., 2024-2025
Asset manager	For	Against	Vote
Fidelity	14,797,352	0	For
Capital Group	9,866,002	1,790	For
Vanguard	9,666,654	801	For
BlackRock	7,267,453	3,075	For
JPMorgan	5,578,034	0	For
State Street	4,188,346	41,343	For
Dodge & Cox	4,066,930	0	For
T. Rowe Price	3,455,811	0	For
Putnam	3,281,882	0	For
GEODE CAPITAL MANAGEMENT, LLC	2,464,390	0	For
Loomis Sayles	1,731,672	44,934	For
Charles Schwab	1,442,407	0	For
Amundi	0	1,202,928	Against
American Century	1,103,703	0	For
Invesco	998,057	0	For
Northern Trust	855,388	5,676	For
AMCAP FUND	803,406	0	For
Nuveen	629,334	0	For
TIAA	595,145	0	For
AllianceBernstein	566,846	0	For
Victory Capital	561,673	0	For
Two Sigma	542,048	0	For
MELLON INVESTMENTS Corp	540,374	0	For
Neuberger Berman	504,534	0	For
INVESTMENT CO OF AMERICA	482,472	0	For

Showing the 25 largest of 966 asset managers. See all 966 in the interactive database.

2. Ratification of the appointment of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2025.

AUDIT-RELATEDMajority of the votes cast: yes

Meeting held 2025-06-13.

Combines 8 wordings of this item as funds reported it.

95% Majority: yes · of votes cast

FOR 95%

FOR: 105,462,255AGAINST: 6,078,716

REGENERON PHARMACEUTICALS INC.’s own tally for this item (“Proposal 2: Ratification of Appointment of Independent Registered Public Accounting Firm The proposal to ratify the appointment of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm”): 105,462,255 for, 6,078,716 against, per its Form 8-K filed 2025-06-18 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 106,700,000 outstanding shares: 99% for, 6% against (100% of the company cast a for/against vote).

The 191 asset managers below cast 99.7% of the shares they voted on this item FOR (39,571,341 for, 104,599 against).

FOR 99.7%

FOR: 39,571,341 (99.7%)AGAINST: 104,599 (0.3%)ABSTAIN: 11,027 (0.0%)NOT VOTED: 337 (0.0%)

Largest asset managers voting on “Ratification of the appointment of PricewaterhouseCoopers LLP as the Company's independent registered public a” at REGENERON PHARMACEUTICALS INC., 2024-2025
Asset manager	For	Against	Vote
Vanguard	8,998,606	1,258	For
Fidelity	7,863,795	0	For
Capital Group	3,988,574	0	For
BlackRock	3,382,678	0	For
Dodge & Cox	1,823,137	0	For
Putnam	1,369,593	0	For
State Street	1,263,298	27	For
JPMorgan	1,162,868	0	For
T. Rowe Price	1,076,500	0	For
AMCAP FUND	803,406	0	For
Charles Schwab	700,123	0	For
TIAA	592,572	0	For
INVESTMENT CO OF AMERICA	482,472	0	For
Victory Capital	464,928	0	For
American Century	464,777	0	For
Loomis Sayles	421,082	0	For
Pacer Funds Trust	384,525	0	For
Invesco	302,826	0	For
Jackson National	251,993	0	For
Dimensional	198,787	0	For
ProShares	184,041	0	For
MASTER INVESTMENT PORTFOLIO	173,159	0	For
Equitable	159,448	0	For
First Trust	158,161	0	For
Aberdeen	156,122	0	For

Showing the 25 largest of 191 asset managers. See all 191 in the interactive database.

3. Election of Directors: Bonnie L. Bassler, Ph.D.

DIRECTOR ELECTIONSMajority of the votes cast: yes

Meeting held 2025-06-13.

Combines 7 wordings of this item as funds reported it.

82% Majority: yes · of votes cast

FOR 82%AGAINST 18%

FOR: 87,348,630AGAINST: 18,594,454

REGENERON PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Bonnie L. Bassler, Ph.D.”): 87,348,630 for, 18,594,454 against, per its Form 8-K filed 2025-06-18 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 106,700,000 outstanding shares: 82% for, 17% against (99.2% of the company cast a for/against vote).

The 188 asset managers below cast 94% of the shares they voted on this item FOR (37,205,813 for, 2,469,570 against).

FOR 94%

FOR: 37,205,813 (93.7%)AGAINST: 2,469,570 (6.2%)ABSTAIN: 11,027 (0.0%)NOT VOTED: 337 (0.0%)

Largest asset managers voting on “Election of Directors: Bonnie L. Bassler, Ph.D.” at REGENERON PHARMACEUTICALS INC., 2024-2025
Asset manager	For	Against	Vote
Vanguard	8,981,262	18,602	For
Fidelity	7,844,889	18,906	For
Capital Group	3,988,574	0	For
BlackRock	3,379,046	3,632	For
Dodge & Cox	1,823,137	0	For
Putnam	1,369,593	0	For
State Street	1,262,773	552	For
JPMorgan	1,162,868	0	For
T. Rowe Price	1,076,500	0	For
AMCAP FUND	803,406	0	For
Charles Schwab	700,123	0	For
TIAA	592,572	0	For
INVESTMENT CO OF AMERICA	482,472	0	For
Victory Capital	33,502	431,426	Against
American Century	464,777	0	For
Loomis Sayles	421,082	0	For
Pacer Funds Trust	384,525	0	For
Invesco	302,826	0	For
Jackson National	248,143	3,850	For
Dimensional	0	198,787	Against
ProShares	0	184,041	Against
MASTER INVESTMENT PORTFOLIO	173,159	0	For
Equitable	106,974	52,474	For
First Trust	0	158,161	Against
Aberdeen	0	156,122	Against

Showing the 25 largest of 188 asset managers. See all 188 in the interactive database.

4. Election of Directors: Michael S. Brown, M.D.

DIRECTOR ELECTIONSMajority of the votes cast: yes

Meeting held 2025-06-13.

Combines 7 wordings of this item as funds reported it.

73% Majority: yes · of votes cast

FOR 73%AGAINST 27%

FOR: 77,025,558AGAINST: 28,913,874

REGENERON PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Michael S. Brown, M.D.”): 77,025,558 for, 28,913,874 against, per its Form 8-K filed 2025-06-18 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 106,700,000 outstanding shares: 72% for, 27% against (99.2% of the company cast a for/against vote).

The 188 asset managers below cast 82% of the shares they voted on this item FOR (32,662,625 for, 7,012,757 against).

FOR 82%AGAINST 18%

FOR: 32,662,625 (82.3%)AGAINST: 7,012,757 (17.7%)ABSTAIN: 11,028 (0.0%)NOT VOTED: 337 (0.0%)

Largest asset managers voting on “Election of Directors: Michael S. Brown, M.D.” at REGENERON PHARMACEUTICALS INC., 2024-2025
Asset manager	For	Against	Vote
Vanguard	8,980,004	19,860	For
Fidelity	5,712,127	2,151,668	For
Capital Group	3,988,574	0	For
BlackRock	3,378,444	4,234	For
Dodge & Cox	1,823,137	0	For
Putnam	1,369,593	0	For
State Street	2,143	1,261,182	Against
JPMorgan	1,162,868	0	For
T. Rowe Price	1,076,500	0	For
AMCAP FUND	803,406	0	For
Charles Schwab	700,016	107	For
TIAA	0	592,572	Against
INVESTMENT CO OF AMERICA	482,472	0	For
Victory Capital	33,502	431,426	Against
American Century	464,777	0	For
Loomis Sayles	421,082	0	For
Pacer Funds Trust	384,525	0	For
Invesco	302,826	0	For
Jackson National	89,171	162,822	Against
Dimensional	0	198,787	Against
ProShares	0	184,041	Against
MASTER INVESTMENT PORTFOLIO	173,159	0	For
Equitable	106,974	52,474	For
First Trust	0	158,161	Against
Aberdeen	0	156,122	Against

Showing the 25 largest of 188 asset managers. See all 188 in the interactive database.

5. Election of Directors: Leonard S. Schleifer, M.D., Ph.D.

DIRECTOR ELECTIONSMajority of the votes cast: yes

Meeting held 2025-06-13.

Combines 7 wordings of this item as funds reported it.

94% Majority: yes · of votes cast

FOR 94%

FOR: 99,271,439AGAINST: 6,672,701

REGENERON PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Leonard S. Schleifer, M.D., Ph.D.”): 99,271,439 for, 6,672,701 against, per its Form 8-K filed 2025-06-18 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 106,700,000 outstanding shares: 93% for, 6% against (99.2% of the company cast a for/against vote).

The 188 asset managers below cast 99.7% of the shares they voted on this item FOR (39,574,760 for, 100,622 against).

FOR 99.7%

FOR: 39,574,760 (99.7%)AGAINST: 100,622 (0.3%)ABSTAIN: 11,027 (0.0%)NOT VOTED: 337 (0.0%)

Largest asset managers voting on “Election of Directors: Leonard S. Schleifer, M.D., Ph.D.” at REGENERON PHARMACEUTICALS INC., 2024-2025
Asset manager	For	Against	Vote
Vanguard	8,999,863	1	For
Fidelity	7,863,795	0	For
Capital Group	3,988,574	0	For
BlackRock	3,382,678	0	For
Dodge & Cox	1,823,137	0	For
Putnam	1,369,593	0	For
State Street	1,263,298	27	For
JPMorgan	1,162,868	0	For
T. Rowe Price	1,076,500	0	For
AMCAP FUND	803,406	0	For
Charles Schwab	700,123	0	For
TIAA	592,572	0	For
INVESTMENT CO OF AMERICA	482,472	0	For
Victory Capital	464,928	0	For
American Century	464,777	0	For
Loomis Sayles	421,082	0	For
Pacer Funds Trust	384,525	0	For
Invesco	302,826	0	For
Jackson National	251,993	0	For
Dimensional	198,787	0	For
ProShares	184,041	0	For
MASTER INVESTMENT PORTFOLIO	173,159	0	For
Equitable	159,448	0	For
First Trust	158,161	0	For
Aberdeen	156,122	0	For

Showing the 25 largest of 188 asset managers. See all 188 in the interactive database.

6. Election of Directors: George D. Yancopoulos, M.D., Ph.D.

DIRECTOR ELECTIONSMajority of the votes cast: yes

Meeting held 2025-06-13.

Combines 8 wordings of this item as funds reported it.

96% Majority: yes · of votes cast

FOR 96%

FOR: 101,367,161AGAINST: 4,089,290

REGENERON PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: George D. Yancopoulos, M.D., Ph.D.”): 101,367,161 for, 4,089,290 against, per its Form 8-K filed 2025-06-18 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 106,700,000 outstanding shares: 95% for, 4% against (99% of the company cast a for/against vote).

The 188 asset managers below cast 99.6% of the shares they voted on this item FOR (39,542,090 for, 133,257 against).

FOR 99.6%

FOR: 39,542,090 (99.6%)AGAINST: 133,257 (0.3%)ABSTAIN: 11,063 (0.0%)NOT VOTED: 337 (0.0%)

Largest asset managers voting on “Election of Directors: George D. Yancopoulos, M.D., Ph.D.” at REGENERON PHARMACEUTICALS INC., 2024-2025
Asset manager	For	Against	Vote
Vanguard	8,998,606	1,257	For
Fidelity	7,863,795	0	For
Capital Group	3,988,574	0	For
BlackRock	3,381,991	687	For
Dodge & Cox	1,823,137	0	For
Putnam	1,369,593	0	For
State Street	1,263,298	27	For
JPMorgan	1,162,868	0	For
T. Rowe Price	1,076,500	0	For
AMCAP FUND	803,406	0	For
Charles Schwab	700,123	0	For
TIAA	592,572	0	For
INVESTMENT CO OF AMERICA	482,472	0	For
Victory Capital	464,928	0	For
American Century	464,777	0	For
Loomis Sayles	421,082	0	For
Pacer Funds Trust	384,525	0	For
Invesco	302,826	0	For
Jackson National	251,993	0	For
Dimensional	198,787	0	For
ProShares	184,041	0	For
MASTER INVESTMENT PORTFOLIO	173,159	0	For
Equitable	159,448	0	For
First Trust	158,161	0	For
Aberdeen	156,122	0	For

Showing the 25 largest of 188 asset managers. See all 188 in the interactive database.

7. Proposal to approve an amendment to the Company's Certificate of Incorporation to declassify the board of directors.

CORPORATE GOVERNANCE

Meeting held 2025-06-13.

Combines 4 wordings of this item as funds reported it.

99.9% fund support · no official result

FOR 99.9%

The 182 asset managers below cast 99.9% of the shares they voted on this item FOR (39,527,585 for, 158 against).

FOR: 39,527,585 (100.0%)AGAINST: 158 (0.0%)ABSTAIN: 232 (0.0%)NOT VOTED: 337 (0.0%)

Largest asset managers voting on “Proposal to approve an amendment to the Company's Certificate of Incorporation to declassify the board of dire” at REGENERON PHARMACEUTICALS INC., 2024-2025
Asset manager	For	Vote
Vanguard	8,999,864	For
Fidelity	7,863,795	For
Capital Group	3,988,574	For
BlackRock	3,382,678	For
Dodge & Cox	1,823,137	For
Putnam	1,369,593	For
State Street	1,263,325	For
JPMorgan	1,162,868	For
T. Rowe Price	1,076,500	For
AMCAP FUND	803,406	For
Charles Schwab	700,123	For
TIAA	592,572	For
INVESTMENT CO OF AMERICA	482,472	For
Victory Capital	464,928	For
American Century	464,777	For
Loomis Sayles	421,082	For
Pacer Funds Trust	384,525	For
Invesco	302,826	For
Jackson National	251,993	For
Dimensional	198,787	For
ProShares	184,041	For
MASTER INVESTMENT PORTFOLIO	173,159	For
Equitable	159,448	For
First Trust	158,161	For
Aberdeen	156,122	For

Showing the 25 largest of 182 asset managers. See all 182 in the interactive database.

8. Amendments to the Company's Certificate of Incorporation to Eliminate Supermajority Vote Requirements Proposal to approve an amendment to Article IV, Section 2(e)(8) of the Certificate of Incorporation

CORPORATE GOVERNANCE

Meeting held 2025-06-13.

Combines 5 wordings of this item as funds reported it.

99.9% fund support · no official result

FOR 99.9%

The 105 asset managers below cast 99.9% of the shares they voted on this item FOR (32,327,197 for, 5,000 against).

FOR: 32,327,197 (100.0%)AGAINST: 5,000 (0.0%)

Largest asset managers voting on “Amendments to the Company's Certificate of Incorporation to Eliminate Supermajority Vote Requirements Proposal” at REGENERON PHARMACEUTICALS INC., 2024-2025
Asset manager	For	Vote
Vanguard	8,997,219	For
Fidelity	7,863,795	For
Capital Group	3,988,574	For
Dodge & Cox	1,823,137	For
Putnam	1,369,593	For
State Street	1,263,325	For
T. Rowe Price	1,076,500	For
AMCAP FUND	803,406	For
TIAA	592,572	For
INVESTMENT CO OF AMERICA	482,472	For
Victory Capital	464,928	For
American Century	464,777	For
Invesco	302,826	For
Dimensional	198,787	For
ProShares	184,041	For
Equitable	159,448	For
First Trust	158,161	For
Aberdeen	156,122	For
Columbia Threadneedle	144,124	For
Thrivent	135,053	For
DWS	123,462	For
Goldman Sachs	109,808	For
Pacific Life	108,116	For
Brighthouse	104,968	For
Prudential/PGIM	103,606	For

Showing the 25 largest of 105 asset managers. See all 105 in the interactive database.

9. Amendments to the Company's Certificate of Incorporation to Eliminate Supermajority Vote Requirements Proposal to approve an amendment to Article VI of the Certificate of Incorporation.

CORPORATE GOVERNANCE

Meeting held 2025-06-13.

Combines 5 wordings of this item as funds reported it.

99.9% fund support · no official result

FOR 99.9%

The 105 asset managers below cast 99.9% of the shares they voted on this item FOR (32,327,197 for, 5,000 against).

FOR: 32,327,197 (100.0%)AGAINST: 5,000 (0.0%)

Largest asset managers voting on “Amendments to the Company's Certificate of Incorporation to Eliminate Supermajority Vote Requirements Proposal” at REGENERON PHARMACEUTICALS INC., 2024-2025
Asset manager	For	Vote
Vanguard	8,997,219	For
Fidelity	7,863,795	For
Capital Group	3,988,574	For
Dodge & Cox	1,823,137	For
Putnam	1,369,593	For
State Street	1,263,325	For
T. Rowe Price	1,076,500	For
AMCAP FUND	803,406	For
TIAA	592,572	For
INVESTMENT CO OF AMERICA	482,472	For
Victory Capital	464,928	For
American Century	464,777	For
Invesco	302,826	For
Dimensional	198,787	For
ProShares	184,041	For
Equitable	159,448	For
First Trust	158,161	For
Aberdeen	156,122	For
Columbia Threadneedle	144,124	For
Thrivent	135,053	For
DWS	123,462	For
Goldman Sachs	109,808	For
Pacific Life	108,116	For
Brighthouse	104,968	For
Prudential/PGIM	103,606	For

Showing the 25 largest of 105 asset managers. See all 105 in the interactive database.

10. PROPOSAL TO APPROVE AN AMENDMENT TO ARTICLE IV, SECTION 2(E)(8) OF THE CERTIFICATE OF INCORPORATION.

SHAREHOLDER RIGHTS AND DEFENSES

Meeting held 2025-06-13.

Combines 4 wordings of this item as funds reported it.

99.9% fund support · no official result

FOR 99.9%

The 86 asset managers below cast 99.9% of the shares they voted on this item FOR (7,191,210 for, 4,086 against).

FOR: 7,191,210 (99.9%)AGAINST: 4,086 (0.1%)ABSTAIN: 10 (0.0%)NOT VOTED: 337 (0.0%)

Largest asset managers voting on “PROPOSAL TO APPROVE AN AMENDMENT TO ARTICLE IV, SECTION 2(E)(8) OF THE CERTIFICATE OF INCORPORATION.” at REGENERON PHARMACEUTICALS INC., 2024-2025
Asset manager	For	Against	Vote
BlackRock	3,380,859	1,819	For
JPMorgan	1,162,868	0	For
Charles Schwab	700,123	0	For
Loomis Sayles	421,082	0	For
Pacer Funds Trust	384,525	0	For
Jackson National	251,993	0	For
MASTER INVESTMENT PORTFOLIO	173,159	0	For
Russell Investments	98,770	0	For
Global X	77,942	0	For
Federated Hermes	50,517	0	For
John Hancock	49,120	0	For
Six Circles Trust	41,096	0	For
SEI	31,231	0	For
ETF Series Solutions	31,019	0	For
VanEck ETF Trust	30,403	0	For
Prudential/PGIM	25,221	0	For
ADAMS DIVERSIFIED EQUITY FUND, INC.	19,700	0	For
NEOS ETF Trust	18,244	0	For
LAUDUS TRUST	17,089	0	For
Natixis	16,717	0	For
ADVISORS' INNER CIRCLE FUND	15,208	0	For
ARK ETF Trust	13,352	0	For
Calamos	13,260	0	For
Baird	12,873	0	For
World Funds Trust	12,755	0	For

Showing the 25 largest of 86 asset managers. See all 86 in the interactive database.

11. Proposal to approve an amendment to Article VI of the Certificate of Incorporation.

CORPORATE GOVERNANCE

Meeting held 2025-06-13.

Combines 3 wordings of this item as funds reported it.

99.9% fund support · no official result

FOR 99.9%

The 86 asset managers below cast 99.9% of the shares they voted on this item FOR (7,191,210 for, 4,086 against).

FOR: 7,191,210 (99.9%)AGAINST: 4,086 (0.1%)ABSTAIN: 10 (0.0%)NOT VOTED: 337 (0.0%)

Largest asset managers voting on “Proposal to approve an amendment to Article VI of the Certificate of Incorporation.” at REGENERON PHARMACEUTICALS INC., 2024-2025
Asset manager	For	Against	Vote
BlackRock	3,380,859	1,819	For
JPMorgan	1,162,868	0	For
Charles Schwab	700,123	0	For
Loomis Sayles	421,082	0	For
Pacer Funds Trust	384,525	0	For
Jackson National	251,993	0	For
MASTER INVESTMENT PORTFOLIO	173,159	0	For
Russell Investments	98,770	0	For
Global X	77,942	0	For
Federated Hermes	50,517	0	For
John Hancock	49,120	0	For
Six Circles Trust	41,096	0	For
SEI	31,231	0	For
ETF Series Solutions	31,019	0	For
VanEck ETF Trust	30,403	0	For
Prudential/PGIM	25,221	0	For
ADAMS DIVERSIFIED EQUITY FUND, INC.	19,700	0	For
NEOS ETF Trust	18,244	0	For
LAUDUS TRUST	17,089	0	For
Natixis	16,717	0	For
ADVISORS' INNER CIRCLE FUND	15,208	0	For
ARK ETF Trust	13,352	0	For
Calamos	13,260	0	For
Baird	12,873	0	For
World Funds Trust	12,755	0	For

Showing the 25 largest of 86 asset managers. See all 86 in the interactive database.

12. 14A Executive Compensation

SECTION 14A SAY-ON-PAY VOTESMajority of the votes cast: yes

Meeting held 2025-06-13.

Combines 14 wordings of this item as funds reported it.

93% Majority: yes · of votes cast

FOR 93%

FOR: 98,781,758AGAINST: 7,100,590

REGENERON PHARMACEUTICALS INC.’s own tally for this item (“Proposal 3: Advisory Vote on Executive Compensation The resolution to approve, on an advisory basis, the compensation of the Company's named executive officers as disclosed in the Company's definitive proxy statement on ”): 98,781,758 for, 7,100,590 against, per its Form 8-K filed 2025-06-18 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 106,700,000 outstanding shares: 93% for, 7% against (99.2% of the company cast a for/against vote).

The 30 asset managers below cast 99.8% of the shares they voted on this item FOR (245,939 for, 484 against).

FOR 99%

FOR: 245,939 (98.7%)AGAINST: 484 (0.2%)A: 2,639 (1.1%)NOT VOTED: 5 (0.0%)

Largest asset managers voting on “14A Executive Compensation” at REGENERON PHARMACEUTICALS INC., 2024-2025
Asset manager	For	Against	Vote
MCDONALD CAPITAL INVESTORS INC/CA	211,483	0	For
BEACON INVESTMENT ADVISORY SERVICES, INC.	24,718	0	For
OLD SECOND NATIONAL BANK OF AURORA	2,858	0	For
Evergreen Wealth Management, LLC	0	0	A
IMA Advisory Services, Inc.	2,020	0	For
PRENTISS SMITH & CO INC	1,387	0	For
River Street Advisors LLC	622	0	For
Baker Avenue Asset Management, LP	582	0	For
Simplify Exchange Traded Funds	476	0	For
Focus Partners Wealth	440	0	For
Schear Investment Advisers, LLC	294	0	For
GAMMA Investing LLC	0	244	Against
Claret Asset Management Corp	188	0	For
Empower	173	0	For
Green Alpha Advisors, LLC	168	0	For
Campion Asset Management	0	150	Against
Game Plan Financial Advisors, LLC	115	0	For
IQ EQ FUND MANAGEMENT (IRELAND) Ltd	105	0	For
ECLECTIC ASSOCIATES INC /ADV	100	0	For
Capital Group	0	90	Against
Lido Advisors, LLC	70	0	For
MQS Management LLC	53	0	For
Wallington Asset Management, LLC	44	0	For
SWEENEY & MICHEL, LLC	23	0	For
Moisand Fitzgerald Tamayo, LLC	13	0	For

Showing the 25 largest of 30 asset managers. See all 30 in the interactive database.

13. Declassify the Board of Directors

CORPORATE GOVERNANCEMajority of the votes cast: yes

Meeting held 2025-06-13.

Combines 2 wordings of this item as funds reported it.

81% Majority: yes · of votes cast

FOR 81%AGAINST 19%

FOR: 85,711,231AGAINST: 20,226,748

REGENERON PHARMACEUTICALS INC.’s own tally for this item (“Proposal 4: Amendment to the Company's Certificate of Incorporation to Declassify the Board of Directors The proposal to amend the Company's Certificate of Incorporation to declassify the board of directors was approved ”): 85,711,231 for, 20,226,748 against, per its Form 8-K filed 2025-06-18 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 106,700,000 outstanding shares: 80% for, 19% against (99.2% of the company cast a for/against vote).

The 8 asset managers below cast 69% of the shares they voted on this item FOR (61,142 for, 27,228 against).

FOR 69%AGAINST 31%

FOR: 61,142 (69.2%)AGAINST: 27,228 (30.8%)

Largest asset managers voting on “Declassify the Board of Directors” at REGENERON PHARMACEUTICALS INC., 2024-2025
Asset manager	For	Against	Vote
GuideStone	32,309	0	For
Erste Asset Management GmbH	0	27,228	Against
Empower	24,879	0	For
HC CAPITAL TRUST	2,019	0	For
CLEARWATER INVESTMENT TRUST	1,378	0	For
Simplify Exchange Traded Funds	476	0	For
NORTHERN LIGHTS FUND TRUST III	80	0	For
VOISARD ASSET MANAGEMENT GROUP, INC.	1	0	For

14. Eliminate Supermajority Vote Requirements of Article VI of Incorporation

SHAREHOLDER RIGHTS AND DEFENSES

Meeting held 2025-06-13.

100% fund support · no official result

FOR 100%

The 5 asset managers below cast 100% of the shares they voted on this item FOR (87,813 for, 0 against).

FOR: 87,813 (100.0%)

Largest asset managers voting on “Eliminate Supermajority Vote Requirements of Article VI of Incorporation” at REGENERON PHARMACEUTICALS INC., 2024-2025
Asset manager	For	Vote
GuideStone	32,309	For
Erste Asset Management GmbH	27,228	For
Empower	24,879	For
HC CAPITAL TRUST	2,019	For
CLEARWATER INVESTMENT TRUST	1,378	For

15. Eliminate Supermajority Vote Requirements of Section 2(e)(8) of Article VI of Incorporation

SHAREHOLDER RIGHTS AND DEFENSES

Meeting held 2025-06-13.

100% fund support · no official result

FOR 100%

The 5 asset managers below cast 100% of the shares they voted on this item FOR (87,813 for, 0 against).

FOR: 87,813 (100.0%)

Largest asset managers voting on “Eliminate Supermajority Vote Requirements of Section 2(e)(8) of Article VI of Incorporation” at REGENERON PHARMACEUTICALS INC., 2024-2025
Asset manager	For	Vote
GuideStone	32,309	For
Erste Asset Management GmbH	27,228	For
Empower	24,879	For
HC CAPITAL TRUST	2,019	For
CLEARWATER INVESTMENT TRUST	1,378	For

16. Proposal to approve, on an advisory basis, executive compensation.

SECTION 14A SAY-ON-PAY VOTESMajority of the votes cast: yes

Meeting held 2024-06-14 (outside the 2024-2025 season's 1 July to 30 June window; reported in this season's filings).

Combines 2 wordings of this item as funds reported it.

95% Majority: yes · of votes cast

FOR 95%

FOR: 106,667,264AGAINST: 5,579,814

REGENERON PHARMACEUTICALS INC.’s own tally for this item (“Proposal 3: Advisory Vote on Executive Compensation The resolution to approve, on an advisory basis, the compensation of the Company's named executive officers as disclosed in the Company's definitive proxy statement on ”): 106,667,264 for, 5,579,814 against, per its Form 8-K filed 2024-06-20 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Share-of-outstanding not shown: votes cast exceed the reported share count, which usually means multiple share classes with different voting rights.

The 4 asset managers below cast 100% of the shares they voted on this item FOR (891 for, 0 against).

FOR 100%

FOR: 891 (100.0%)

Largest asset managers voting on “Proposal to approve, on an advisory basis, executive compensation.” at REGENERON PHARMACEUTICALS INC., 2024-2025
Asset manager	For	Vote
COLDSTREAM CAPITAL MANAGEMENT INC	618	For
Ipswich Investment Management Co., Inc.	234	For
Americana Partners, LLC	39	For
Echo45 Advisors LLC	0	--

17. Elimination of Supermajority Requirement Relating to Removal of Directors

SHAREHOLDER RIGHTS AND DEFENSES

Meeting held 2025-06-13.

100% fund support · no official result

FOR 100%

The 3 asset managers below cast 100% of the shares they voted on this item FOR (70,582 for, 0 against).

FOR: 70,582 (100.0%)

Largest asset managers voting on “Elimination of Supermajority Requirement Relating to Removal of Directors” at REGENERON PHARMACEUTICALS INC., 2024-2025
Asset manager	For	Vote
Cardano Risk Management B.V.	58,342	For
Impact Asset Management GmbH	6,480	For
AMERICAN BEACON FUNDS	5,760	For

18. Elimination of Supermajority Requirement Relating to the Mandatory Conversion of Class A Stock to Common Stock

EXTRAORDINARY TRANSACTIONS

Meeting held 2025-06-13.

100% fund support · no official result

FOR 100%

The 3 asset managers below cast 100% of the shares they voted on this item FOR (70,582 for, 0 against).

FOR: 70,582 (100.0%)

Largest asset managers voting on “Elimination of Supermajority Requirement Relating to the Mandatory Conversion of Class A Stock to Common Stock” at REGENERON PHARMACEUTICALS INC., 2024-2025
Asset manager	For	Vote
Cardano Risk Management B.V.	58,342	For
Impact Asset Management GmbH	6,480	For
AMERICAN BEACON FUNDS	5,760	For

19. Repeal of Classified Board

DIRECTOR ELECTIONS

Meeting held 2025-06-13.

100% fund support · no official result

FOR 100%

The 3 asset managers below cast 100% of the shares they voted on this item FOR (70,582 for, 0 against).

FOR: 70,582 (100.0%)

Largest asset managers voting on “Repeal of Classified Board” at REGENERON PHARMACEUTICALS INC., 2024-2025
Asset manager	For	Vote
Cardano Risk Management B.V.	58,342	For
Impact Asset Management GmbH	6,480	For
AMERICAN BEACON FUNDS	5,760	For

20. Election of Directors

SECTION 14A SAY-ON-PAY VOTES

Meeting held 2025-06-13.

All nominees (reported as one line). These filers reported the election of directors as a single line covering every nominee. It is not attributed to any one director, and no share total is shown for it.

Combines 2 wordings of this item as funds reported it.

100% fund support · no official result

FOR 100%

The 2 asset managers below cast 100% of the shares they voted on this item FOR.

FOR: 100.0%

Largest asset managers voting on “Election of Directors” at REGENERON PHARMACEUTICALS INC., 2024-2025
Asset manager	For	Against	Abstain	Withheld	Vote
Green Alpha Advisors, LLC	672	0	0	0	For
Bell & Brown Wealth Advisors, LLC	2	0	0	0	For

21. Approve Article Amendments

OTHER

Meeting held 2025-06-13.

100% fund support · no official result

FOR 100%

The 2 asset managers below cast 100% of the shares they voted on this item FOR (477 for, 0 against).

FOR: 477 (100.0%)

Largest asset managers voting on “Approve Article Amendments” at REGENERON PHARMACEUTICALS INC., 2024-2025
Asset manager	For	Against	Abstain	Withheld	Vote
Simplify Exchange Traded Funds	476	0	0	0	For
VOISARD ASSET MANAGEMENT GROUP, INC.	1	0	0	0	For

22. Election of Directors (Majority Voting)

DIRECTOR ELECTIONS

Meeting held 2025-06-13.

100% fund support · no official result

FOR 100%

The 2 asset managers below cast 100% of the shares they voted on this item FOR.

FOR: 100.0%

Largest asset managers voting on “Election of Directors (Majority Voting)” at REGENERON PHARMACEUTICALS INC., 2024-2025
Asset manager	For	Against	Abstain	Withheld	Vote
Simplify Exchange Traded Funds	476	0	0	0	For
VOISARD ASSET MANAGEMENT GROUP, INC.	1	0	0	0	For

Largest REGENERON PHARMACEUTICALS INC. shareholders voting in 2024-2025

Ranked by the number of REGENERON PHARMACEUTICALS INC. shares each manager voted on the most widely held ballot item of the 2024-2025 meeting, shown as a share of the 106,700,000 shares outstanding at the time of that meeting.

Top REGENERON PHARMACEUTICALS INC. shareholders by shares voted, 2024-2025
#	Asset manager	% of shares outstanding
1	Fidelity	13.87%
2	Capital Group	9.25%
3	Vanguard	9.06%
4	BlackRock	6.81%
5	JPMorgan	5.23%
6	State Street	3.96%
7	Dodge & Cox	3.81%
8	T. Rowe Price	3.24%
9	Putnam	3.08%
10	GEODE CAPITAL MANAGEMENT, LLC	2.31%

Reported REGENERON PHARMACEUTICALS INC. ownership

Positions disclosed to the SEC on Schedules 13D and 13G, Form 13F and the company’s own proxy statement (DEF 14A).

REGENERON PHARMACEUTICALS INC. beneficial owners on record for the 2024-2025 proxy season
Holder	% outstanding	Disclosure
The Vanguard Group, Inc.	8.28%	DEF14A
BlackRock, Inc.	8.09%	DEF14A
State Street	4.49%	13F
JPMORGAN CHASE & CO.	4.44%	13G
FMR LLC	3.15%	13G
Geode Capital	2.31%	13F
Franklin Templeton	2.13%	13F
T. Rowe Price	2.04%	13F
Leonard S. Schleifer, M.D., Ph.D.	1.62%	DEF14A
Morgan Stanley	1.17%	13F

Percentages above are of 106,700,000 shares outstanding, as reported by REGENERON PHARMACEUTICALS INC. on its Form 10-Q dated 2025-03-31 (see the filing on EDGAR). This is the count contemporaneous with the 2024-2025 meeting, so the percentages are the ones that were true then, not ones restated against today’s share count.

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered investment companies and institutional managers disclose how they voted every proxy, and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from REGENERON PHARMACEUTICALS INC.’s 10-Q dated 2025-03-31. This page is a static snapshot rebuilt weekly on 02 October 2026; a live search always shows the current data.

At REGENERON PHARMACEUTICALS INC.'s shareholder meeting held 2025-06-13, in the 2024-2025 proxy season, 1,011 asset managers reported how they voted in their SEC Form N-PX filings, covering 10,208 separate fund positions. Their filings are grouped here into 22 reported items; because filers word the same ballot item differently, that can be more than the number of items on the ballot. REGENERON PHARMACEUTICALS INC.'s own Form 8-K tally for this meeting is published below, but no row in it could be matched to the most widely held item, so this page states no certified outcome for that item. On that item — Proposal to approve on an advisory basis executive compensation. — the reporting funds cast 95% of the shares they voted in favour (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). That is the aggregate of those managers' own N-PX disclosures, not the company's certified result, and the funds are a subset of all shareholders.

REGENERON PHARMACEUTICALS INC. proxy season coverage: 2023-2024 · 2024-2025 (this page) · 2025-2026.